Clinical Trial Update: A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual Disease in Colorectal Cancer After Completion of Adjuvant Chemotherapy [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating Fruquintinib in combination with tislelizumab for ctDNA-defined minimal residual disease in colorectal cancer after adjuvant chemothe…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer

Drugs mentioned

• Fruquintinib (fruquintinib)
• Tislelizumab (tislelizumab)

Snippet

Sponsor: M.D. Anderson Cancer Center | Conditions: Minimal Residual Disease, Adjuvant Chemotherapy | Phase 2 | Status: RECRUITING